VEGFA and myasthenia gravis: In the current study, we used the nAMD fibrovascular membrane rat model to comprehensively evaluate the effects of MG combined with the anti-VEGF agent ranibizumab from histomorphological and molecular biological approaches, respectively, and tried to reveal the mechanism of action.